Commentary
Video
Dr. Dmochowski on tibial nerve stimulation as an earlier line of therapy for OAB
Author(s):
Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.
Video Player is loading.
In this video, Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the BlueWind Revi System, specifically touching on how the device is being recognized as a potential earlier line of therapy for patients with overactive bladder (OAB). Dmochowski is the chief medical officer at BlueWind Medical as well as a professor of urology, gynecology, and surgery and Vanderbilt University Medical Center in Nashville, Tennesee.
Related Videos
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Pain management disparities in kidney stones point to need for guidelines, experts say
John Taylor, III, MD, on novel options in NMIBC
FDA testosterone labeling changes: How will they affect prescribing?
Why a personalized approach is key to prolapse and OAB management
Timothy Lyon, MD, highlights study assessing accuracy of urology rankings
Related Content
